



BIODESCONTAMINACIÓN

STERIS BIODECON VHP®


Vapor de Peróxido de Hidrógeno

Julian Pons
Steris Iberia S.A.U.





Importancia de la Desinfección Ambiental



EVIDENCIA CIENTÍFICA DEL PAPEL DEL MEDIO-AMBIENTE EN LA TRANSMISIÓN



Intensive care unit environmental surfaces are contaminated by multidrug-resistant bacteria in biofilms: combined results of conventional culture, pyrosequencing, scanning electron microscopy, and confocal laser microscopy

[H. Hu](#), [K. Johani](#), [J.B. Goebel](#), [A.S.W. Jacombs](#), [A. Almatroudi](#), [G.S. Whiteley](#), [A.K. Dey](#), [S. Jensen](#), [K. Vicker](#) 

Received: March 17, 2015; Accepted: May 26, 2015; Published Online: June 25, 2015

Risk of organism acquisition from prior room occupants: a systematic review and meta-analysis

[B.G. Mitchell](#) , [S.J. Dancer](#), [M. Anderson](#), [E. Dehn](#)

Received: June 8, 2015; Accepted: August 4, 2015; Published Online: August 21, 2015

Publication stage: In Press Accepted Manuscript

LIMPIEZA Y DESINFECCIÓN CONVENCIONAL

Box 1

Summary of problems associated with conventional cleaning and disinfection

Problems associated with the cleaning/disinfection products include:

- Infectiveness of some agents against some pathogens; for example, many frequently used hospital disinfectants are not effective against *C. difficile* spores and norovirus.^{44,85,134}
- Toxicity to staff or the environment.^{44,46}
- Damage to hospital materials and equipment.⁴⁴
- Susceptibility to interference with organic matter on surfaces.⁸⁵
- Potential for biocide/antibiotic cross-resistance.⁸²

Problems with cleaning/disinfection procedures include:

- Adequate distribution of the active agent, given the challenges of the complex hospital environment.³⁵
- Ensuring correct contact time for the microbial reduction achieved *in vitro*.¹³⁴
- Repeatability of the process depends on the operator.³⁵
- Designation of responsibility for various items, particularly complex portable medical equipment.¹³⁵
- Compliance with protocols/policies from an (often) poorly paid, poorly motivated workforce.¹³⁶
- Inadequate training and education of personnel.¹³⁶
- Inadequate time given to do the job properly.¹³⁶
- Insufficient (or non-existent) cleaning prior to disinfection.⁸⁵
- Incorrect formulation of the disinfectant.^{82,137}
- Contamination of cleaning solutions/materials.^{137,138}
- The effectiveness of conventional cleaning and disinfection is difficult to monitor.¹¹

PROBLEMAS CON
LOS PRODUCTOS


PROBLEMAS CON LOS
PROCEDIMIENTOS

From J.A. Otter et al. *Journal of Hospital Infection* 83 (2013) 1-13

CUESTIONES Y PREOCUPACIONES SOBRE LA LIMPIEZA HOSPITALARIA



RESISTENCIA RELATIVA DE LOS MICROORGANISMOS A PROCESOS DE BIODESCONTAMINACIÓN



PERSISTENCIA DE LOS MICROORGANISMOS (CLÍNICAMENTE RELEVANTES) EN SUPERFICIES SECAS INORGÁNICAS

<u>TIPO</u>	<u>DURACIÓN DE PERSISTENCIA (RANGO)</u>
-------------	---

Bacterias:

Acinetobacter	3 días - 5 meses
Clostridium difficile (esporas)	5 meses
Mycobacterium tuberculosis	1 día - 4 meses
Staphylococcus Aureus (incl SARM)	7 días - 7 meses
Enterococcus Incl VRE	5 días - 4 meses

Virus:

Coronavirus	3 horas
Virus asociados al SARS	72 - 96 horas
Norovirus y FCV	8 horas a 7 días

Referencia: *BMC Infectious diseases journal* 2006 6:130

www.biomedcentral.com


**¿QUÉ PRODUCTOS Y TECNOLOGÍAS DEBERÍAN SER USADAS CONTRA LOS
DIFERENTES TIPOS DE PATÓGENOS?**

TECNOLOGÍA VHP®




VHP® (PERÓXIDO DE HIDRÓGENO VAPORIZADO)

Proceso de baja temperatura




35%

Vaporización



Esporicida en Bajas Concentraciones
(Valor típico 0.5-2 mg/l a 25°C)

**Dos ciclos validados para
reducción 6log Geob. Stearoth.**



Residuos no tóxicos

**250 ppm - 90 min
400 ppm - 30 min**

INOCUO PARA EL MEDIO AMBIENTE, CON UNA EXCELENTE SEGURIDAD,
VAPOR SECO, INODORO, INCOLORO, NO CORROSIVO,
SEGURO ELÉCTRICAMENTE, COMPLETAMENTE VALIDABLE

VHP® - VAPORIZACIÓN


- Volumen y forma del Vaporizador
- Temperatura Vaporización 100º
- Caudal de Aire 34 m³ / hora
- Inyección de H₂O₂ al 35% max. 12 gr/min por medio de tres agujas con distribución espacial
- **Resultado final aire con Peróxido de Hidrógeno al 35% vaporizado sin condensación.**



CICLO TÍPICO DEL VHP® - GAS



CICLO TÍPICO DE DESCONTAMINACIÓN CON SISTEMAVHP.



Registrado, EPA Agencia Americana Protección Ambiental, por el Ministerio de Sanidad y la AEMPS

Aprobado por la US EPA (Environmental Protection Agency)
(Registro No. 58779-4) Septiembre de 2006.

Aprobado por el Ministerio de Sanidad – Sanidad Ambiental y Salud Laboral. Nº de Registro
10-20/40-05814. Julio 2010

Permite el uso del esterilizante Vaprox y sus aplicaciones

Bactericida, Fungicida, Viricida y Esporicida



VERIFICACIÓN DEL CICLO VHP® EN UNA HABITACIÓN



1. VHP®: Indicadores Biológicos y Químicos VAPROX



2. MONITORIZACIÓN INDEPENDIENTE DEL CICLO:

Concentración H_2O_2 de VHP®

Humedad



Temperatura

Niveles residuales de gas < 1ppm

3. TOMA DE MUESTRAS DE SUPERFICIES

4. TOMA DE MUESTRAS DE AIRE

VERIFICACIÓN DEL CICLO VHP® - QUIMICOS, BIOLOGICOS, UBICACIONES



SISTEMAS Y PRODUCTOS DE BIODESCONTAMINACIÓN VHP® SUS APLICACIONES




EQUIPO Y ACCESORIOS VHP®



CARACTERÍSTICAS BÁSICAS:

- Puede bio-descontaminar zonas de hasta 300 m³.
- Control remoto del ciclo vía PC y visor de Windows tipo VNC.
- Registro de todos los datos del ciclo en PenDrive.
- Sistemas de red VHP® 1000-ARD para aplicaciones en áreas de gran volumen.
- Accesorios opcionales para optimizar ciclos. Aireadores, Deshumidificadores.

INTEGRADO EN LA CLIMATIZACIÓN



Clima en Marcha
Inyección VHP en Conducto
Recirculación por conductos y UTA



APLICACIONES Y ESTUDIO DE CASOS PRÁCTICOS



NO SE TRATA DE UNA NUEVA TECNOLOGÍA

Más de 1800 sistemas VHP® en todo el mundo, incluyendo clientes tales como:

Abbott Laboratories, Abiogen Pharma, Acambis, Acusphere, Alcon, Alkermes, Alpha Therapeutics, Allergan, Altana, Alza, Amersham, Amriya, Aradigm, Asta Medica, Astra-Zeneca, Aventis Pasteur, Aventis Pharma, B.Braun, Bausch & Lomb, Baxter, Bayer, Beaumont Hospital, Dublin, Bigmar Pharma, Biochemie, Biochem Vaccines, Bioglan, Biogen, Biomet, Bioproduct Research, Bioreliance, Biotissue, Boeringher Ingelheim, Bristol-Meyers Squibb, Carbomedics, Cardinal Healthcare, Ciba Vision, Cilag, CBL, Corixa, CP Pharmaceuticals, Depuy CMW, Dey Laboratories, Dr.Kade, Dupont Merck, Eisai, Eli Lilly, Essex, Ethicon, Ferrero, Ferring, Fisons-Aventis, Fort Detrick, Fort Dodge, Fresenius, Fujisawa, GBF, G.C. Hanford, Genetech, Genzyme, Glaxo Sminth Kline, Gruenthal, Gruppo Lepetit, Haupt Pharma, Health Canade, Heinrich Pette Institut, Hemosol, Hikma Pharmaceutical, Hoffmann La Roche, Howmedica, Imperial College London, IVAX Laboratories, Karolinska University, Jackson Laboratories, Janssen, Johnson & Johnson, Knoll, Lancaster Laboratories, Leciva, Lederle laboratories, Life technologies, Lohmann Animal Health, LPI, Mallinkrodt Nuclear laboratories, Marsam Pharmaceutical, Max Plank Institut, Mead-Johnson, Mediva, Medtronic, Megabios, Merck, Merial, Meridian Medical, Monsanto, MBZ, MHH, MSD, MRC, Murinus, Nelson Labs, Nordian, Nordmark, Novartis, Nova Pharmaceutical, Novo Nordisk, Nu-Pharm, Nycomed, OJM Pharmaceutical, Oncotec, Orthivita, Osteotech, OZBT, Patheon, Pasteur-Merieux, Pfizer, Pharmacia & Upjohn, Pierre Fabre, Powderjet, PSI, Purdue Biopharma, Ribbon, Rhone Merieux, Roche Pharmaceutical, Roche diagnostics, RPR-Fisons, RVH Belfast, Sandoz, Sanofi Aventis, Schein Pharmaceutical, Schering-Plough, Sintetica, Solvay Pharma, South Dakota State University, Stowers Institute, SIFI, Sulzer Mitroflow, Systemix, Teva Pharmaceutical, Transgene, Smith & Nephew, Royal College of Surgeons Dublin, Tyco, UKE, Unilever, Union Chimique Belge, University of Bielefeld, University of Cambridge, University of Dresden, University of Durham, University of Erlangen, University of Edinburgh, University of Jena, University of Magdenburg, University of Oxford, University of Tennessee, University of Cork, University of WI, University of Zurich, US Army, Vistakon, Walter Reed Army Institute, Warner Lambert, Wyeth, Zenit.

APLICACIONES DE HOTELARIA HOSPITALAR

Dairy, Food and Environmental Sanitation, Vol. 22, No. 11, Pages 868-873
Copyright© International Association for Food Protection, 6200 Aurora Ave., Suite 200W, Des Moines, IA 50322

Vapor Phase Hydrogen Peroxide Decontamination of Food Contact Surfaces

Gerald McDonnell,* George Grignol, and Kathy Antloga
Research & Development, STERIS Corporation
5960 Heisley Road, Mentor, OH 44060-1834

APLICACIONES DE HOTELARIA HOSPITALAR

2007 Steris named global supplier to Tetra Pak

STERIS and Tetra Pak Sign Joint Development Agreement

Collaborative Efforts Will Leverage Each Company's Core Capabilities

BEBERAGE FILLING STERILIZATION

Tetra Pak tests new sterilisation systems in joint deal

APLICACIONES TÍPICAS HOSPITALARIAS



Quirófanos



Cuidados Intensivos



Neonatos / Incubadoras



Habitaciones/salas
de aislamiento




Habitaciones/Áreas de
Biodescontaminación de equipos





**Hospital
Curry Cabral**

Habitación Infecciosos





Distribuição e localização dos equipamentos

Sistema VHP-ARD Sterils

- ① VHP-generador de vapor H₂O₂
- ② Sensor de H₂O₂
- ③ Ventilador


Mobiliário, equipamento

- ④ Cama
- ⑤ Mesa apoio
- ⑥ Mesa e Equipamento de Monitorização



Almacén de Material Estéril

280 m³



Distribuição e localização dos equipamentos

Sistema VHP-ARD Steris
① VHP-generador de vapor H2O2
② Sensor de H2O2
③ Ventilador

Localização dos Indicadores Químicos H2O2

④ A = Alto
⑤ B = Baixo

Localização dos Controles Biológicos

Grupo formado por




⑥ Esporas Geobacillus 10E06
⑦ Indicador Químico





4. CONCLUSÕES

O presente estudo teve como objetivo comparar a contaminação microbiológica do ar no armazém de esterilizados, antes e após uma biodescontaminação utilizando Peróxido de Hidrogénio Vaporizado (VHP®). Os resultados obtidos indicam que a biodescontaminação levada a cabo reduziu a contaminação microbiológica do ar para níveis compatíveis com as atividades a que a sala se destina.



VHP® INFORME RESULTADOS – CICLO DESCONTAMINACIÓN EBOLA



BIODECON VHP® - UCI COMPLETA



BIODECON VHP® - PEDIATRIA-NIDOS NEONATOS



USO DEL PERÓXIDO DE HIDRÓGENO EN VAPOR EN EL CONTROL DE UN BROTE NOSOCOMIAL POR *KLEBSIELLA BLEE*



Lucerna Méndez, MA; Maldonado Valverde, MC; Cabezas Fernández, T; Lozano Serrano, A; Fernández Martín, J; Cañabate Reche, F.
Agencia Sanitaria Poniente de Almería. E-mail: mariaangeles.lucerna@ephpo.es

INTRODUCCIÓN

En noviembre de 2012, se detectó un brote nosocomial por *Klebsiella pneumoniae* productora de beta-lactamasa de espectro extendido (BLEE) en la sala de neonatos del hospital de Poniente de Almería.

OBJETIVO: Evaluar el uso de la descontaminación con peróxido de hidrógeno en vapor en el control de brotes nosocomiales.

MÉTODOS

Estudio observacional descriptivo.

Se realiza investigación epidemiológica de afectados y búsqueda activa de casos.

Se han inoculado sobre distintas superficies cepas en suspensión de *klebsiella* BLEE y MRSA (10^5 ufc), muestreando tras la aplicación del peróxido para comprobar su efectividad, además se han distribuido controles químicos y biológicos en tres dependencias del área de neonatos antes de su descontaminación (sala de hospitalización de neonatos dividida en dos zonas y lactario).



RESULTADOS

Se identificaron 3 casos y 8 portadores perineales, de 110 expuestos. Se realizaron 3 descontaminaciones con peróxido de hidrógeno (un ciclo por sala). Se repartieron 16 controles químicos y 3 biológicos en cada sala, todos presentaron resultados correctos.



De las 12 superficies inoculadas con gérmenes multirresistentes, sólo 1 fue positiva (2 ufc). Tras 3 meses de vigilancia después de la detección del último caso se consideró erradicado el brote.

Tabla 1. SUPERFICIES MUESTREADAS CON CEPAS DE *KLEBSIELLA BLEE* SALAS DE NEONATOLOGÍA

	Superficie	Resultado
SALA 1 NEONATOLOGÍA	Equipo de radiología portátil	0 ufc
	Equipo de radiología portátil	0 ufc
	Equipo de radiología portátil	0 ufc
	Equipo de radiología portátil	0 ufc
SALA 2 NEONATOLOGÍA	Equipo de radiología portátil	0 ufc
	Equipo de radiología portátil	0 ufc
	Equipo de radiología portátil	0 ufc
	Equipo de radiología portátil	0 ufc
LACTARIO	Equipo de radiología portátil	0 ufc
	Equipo de radiología portátil	0 ufc
	Equipo de radiología portátil	0 ufc
	Equipo de radiología portátil	0 ufc

Tabla 2. SUPERFICIES MUESTREADAS CON CEPAS DE *STAPHYLOCOCCUS AUREUS* METICILINA RESISTENTE SALAS DE NEONATOLOGÍA

	Superficie	Resultado
SALA 1 NEONATOLOGÍA	Equipo de radiología portátil	0 ufc
	Equipo de radiología portátil	0 ufc
	Equipo de radiología portátil	0 ufc
	Equipo de radiología portátil	0 ufc
SALA 2 NEONATOLOGÍA	Equipo de radiología portátil	0 ufc
	Equipo de radiología portátil	0 ufc
	Equipo de radiología portátil	0 ufc
	Equipo de radiología portátil	0 ufc
LACTARIO	Equipo de radiología portátil	0 ufc
	Equipo de radiología portátil	0 ufc
	Equipo de radiología portátil	0 ufc
	Equipo de radiología portátil	0 ufc

DISCUSIÓN

Además de la aplicación del peróxido de hidrógeno, se introdujeron otras medidas para el control del brote: limpieza y desinfección de incubadoras y cunas; separación de colonizados/infectados de otros pacientes; dedicación de personal exclusivo para la atención de casos; alta precoz de pacientes; aislamiento de contacto estricto y refuerzo de la higiene de manos.

CONCLUSIONES

El uso del peróxido de hidrógeno en vapor puede contribuir a la erradicación de brotes nosocomiales por *klebsiella* BLEE complementando otras medidas de control de la infección.



Control of an outbreak of *Acinetobacter baumannii* infections using vaporized hydrogen peroxide


A. Chmielarczyk^{a,*}, P.G. Higgins^b, J. Wojkowska-Mach^a, E. Synowiec^c,
E. Zander^b, D. Romaniszyn^a, T. Gosiewski^a, H. Seifert^b, P. Heczko^a,
M. Bulanda^a

^a Jagiellonian University Medical College, Krakow, Poland

^b Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany

^c John Paul II Regional Teaching Hospital, Krakow

A. Chmielarczyk et al. / Journal of Hospital Infection 81 (2012) 239–245



APLICACIONES DE STERIS VHP®

BIODESCONTAMINACIÓN

STERIS Defense & Industrial Group Case Study

Anthrax Remediation of U.S. State Department Mail Facility SA-32

The Challenge:

The U.S. State Department Mail Facility in Sterling, Virginia was contaminated with Anthrax spores after accepting mail from the Brentwood Post Office in Washington, D.C. in October 2001. The State Department was forced to abandon and quarantine the facility, and was seeking a safe, environmentally friendly and non-corrosive means of remediation.

The Solution:

STERIS's proprietary vaporized hydrogen peroxide technology (VHP®) was selected as the project decontaminate after the State Department's Technical Working Group (TWG) compared and evaluated available remediation technologies. The group, which included representatives from the State Department, the U.S. Environmental Protection Agency, Centers for Disease Control and Prevention, Occupational Health and Safety Administration, Army Corps of Engineers and the State of Virginia utilized criteria such as efficacy, safety, material compatibility, business continuity, and industry experience with the technology in making their selection.

In use for over a decade with STERIS's pharmaceutical and research customers, the VHP technology was modified by STERIS's Defense & Industrial (D&I) Group for application in large-scale, complex, building interiors. The VHP technology is highly effective against pathogenic organisms and bacterial spores, and unlike many other antimicrobials, it breaks down into water vapor and oxygen. Additionally, the technology will not produce hazardous substances, is environmentally friendly, non-carcinogenic, non-corrosive at use concentration, and does not leave residues.

Because the STERIS VHP system employs a low concentration, dry process, it is compatible with a wide variety of materials, including sensitive electronics, equipment, and a broad range of materials and finishes. It can be used over a wide range of temperatures, works quickly, and because of its scalability, is effective in small or spacious areas.

In addition to providing its VHP technology, the STERIS D&I Group developed a comprehensive remedial action plan and health and safety protocols that were utilized in the successful decontamination of the facility. As



A STERIS Defense & Industrial technician collects biological indicators which were used to validate the efficacy of the decontamination process.

part of its comprehensive initiative, STERIS D&I also drafted and supplied quality and sterility assurance protocols.

The Result:

Remediation of SA-32 occurred between July and August 2003, and was cleared for reuse on December 5, 2003. The approach for decontamination of SA-32 was based on the goal of treating the entire facility section by section, dividing areas into no more than 200,000 cubic feet. These zones were fumigated with VHP as part of a controlled, staged process. In preparation for fumigation, the facility was separated into 10 areas using partitions constructed from polyethylene sheeting with wooden 2' x 4' supporting structures. VHP was pumped into these zones through air intake ducts erected for this purpose.

Measured by real-time VHP concentration monitors, the VHP process met the prescribed specifications and process variables for each of the four phases of the decontamination cycle. Prior to applying the VHP sterilant, chemical and biological indicators were placed throughout the facility. Following VHP application,

chemical indicators exhibited the required colorimetric changes and biological indicators were negative for growth of the indicator organism. Numerous surfaces throughout the facility were swabbed, cultured, and analyzed by methods approved by the Naval Medical Research Center, Silver Springs, Maryland. All 619 samples were negative for *Bacillus anthracis*.

The Environmental Clearance Committee (ECC) stated that the remediation approach used at the facility was thorough in both design and implementation. The ECC achieved its goal of using the best science and technology available to minimize residual risk to the greatest extent possible. The ECC concluded that the decontamination process for the facility as set forth by the TWG and performed by the State Department Project Team, which included STERIS, was safely and effectively completed.



Large scale VHP decontamination system deployed at the U.S. State Department mail processing center in Sterling, Virginia.

To learn more about the STERIS Defense & Industrial Group, visit www.steris.com or call Kevin Marsh at 440-392-7660.



M2712EN 2004-10, Rev. A © 2004 STERIS Corporation. All rights reserved.

POST OFFICE, WASHINGTON (US). Contaminación: ANTHRAX

SISTEMAS DE DESINFECCIÓN HOSPITALARIA





PATHOGON™



VHP™



VHP™ Integrado



SERVICIOS



VAPROX CONTROLES





VAPROQUIP™

PATHOGON - Desinfección por UVC

VHP® BIODECON
STERIS

- Dentro del espectro de luz UV, solo un pequeño intervalo (257 nM) esta comprobado como el mas germicida.





Tecnología
STERIS VHP®

GRACIAS POR SU
ATENCIÓN



Associação Portuguesa de
Hotelaria Hospitalar

STERIS®

